First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
Pharmacology, Toxicology and Pharmaceutical Science
1
6%
Immunology and Microbiology
1
6%
Economics, Econometrics and Finance
1
6%
Other
1
6%
Unknown
8
47%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 July 2022.
All research outputs
#6,413,935
of 22,788,370 outputs
Outputs from Journal of Clinical Oncology
#10,843
of 19,917 outputs
Outputs of similar age
#127,767
of 440,036 outputs
Outputs of similar age from Journal of Clinical Oncology
#454
of 809 outputs
Altmetric has tracked 22,788,370 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 19,917 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.3. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,036 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 809 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
